郵箱: qrding@sinh.ac.cn
電話: +86-21-54920998
所屬部門: 營養(yǎng)代謝與食品安全重點實驗室
2017-至???今：中國科學(xué)院上海營養(yǎng)與健康研究所 研究員
2014-2016年：中國科學(xué)院上海生命科學(xué)研究院營養(yǎng)科學(xué)研究所 研究員
2010-2014年：美國哈佛大學(xué)干細(xì)胞研究所、干細(xì)胞與轉(zhuǎn)化生物學(xué)系 博士后
2004-2010年：中國科學(xué)院上海生命科學(xué)研究院營養(yǎng)科學(xué)研究所 博士
2000-2004年：南京大學(xué)生物科學(xué)系 學(xué)士
多能干細(xì)胞與肝臟疾病
1. 基于人多能干細(xì)胞的疾病研究和靶向治療
????利用患者來源的誘導(dǎo)性多能干細(xì)胞（iPSC）或者體外建立的疾病胚胎干細(xì)胞（ESC），結(jié)合基因編輯和定向分化平臺，在功能基因組水平研究人類肝臟疾病的分子機(jī)理，發(fā)現(xiàn)新型靶標(biāo)；發(fā)展基于干細(xì)胞疾病模型的藥物篩選和毒理評價體系；進(jìn)行藥物化合物篩選，研發(fā)針對特定靶標(biāo)的藥物先導(dǎo)化合物；優(yōu)化體外多能干細(xì)胞肝向分化平臺，建立肝臟異種嵌合動物模型，探索基于人多能干細(xì)胞來源的肝臟細(xì)胞作為肝移植潛在肝源的可行性。
2. 肝臟脂代謝紊亂的遺傳及表觀遺傳基礎(chǔ)
????結(jié)合干細(xì)胞疾病模型、基因編輯在體大規(guī)模篩選和人群疾病遺傳學(xué)分析，研究肝臟脂代謝紊亂及其導(dǎo)致的肝再生能力下降的遺傳和表觀遺傳基礎(chǔ)，探索預(yù)防和治療包括脂肪肝、肝纖維化等肝病的方法和手段。
3. 代謝疾病的基因治療研究
????針對高甘油三酯血癥、高膽固醇血癥、腫瘤惡病質(zhì)等代謝疾病，以CRISPR/Cas9在體靶向技術(shù)為基礎(chǔ)，篩選新型靶標(biāo)，優(yōu)化基因治療方案，開展臨床前研究。
1. Tian C#*, Guo X#, Wang D, Chen Q, Shen H, Li X, Liu C, Qi Y, Chen Y, Wang L,Wang Y, Cao Y, Liu Y, Yin H, Chen Y, Gu X, Jiang C*, Tang L*, Xie C*, Ding Q*. Uric acid promotes dietary lipid absorption through microbiome and metabolomic remodeling via a liver-gut endocrine axis. Cell Host Microbe. 2026. Jun 3:S1931-3128(26)00181-2. doi: 10.1016/j.chom.2026.05.005.
2. Zhang Y, Wang Y, Li B, Li X, Liu C, Chen Y, Tian C, Wang D, Gu X, Jiang C*, Wei Y*, Ding Q*. Selenoprotein H Functions as a PPARα Coactivator to Link Selenium Homeostasis to Hepatic Lipid Metabolism and Protect against Steatohepatitis. Adv Sci (Weinh). 2026. 13(22):e19563.
3. Jiang D, Wang Y, Chen Y, Tian C, Li X, Li S, Gu X, Jiang C*, Ding Q*.Mitochondrial Pyruvate Carrier Differentially Controls the Self-Renewal and Differentiation of Human Pluripotent Stem Cells. J Cell Physiol. 2025. 240(8):e70083.
4. Qi Y, He X, Wu X, Zhou T, Liang N, Jiao J, Chen Y, Yuan Y, Zhang Y, Wang Y, Liu Y, Ding Q*. Identification of deferasirox as a human xanthine oxidase inhibitor. Life Med. 2025. 4(2): Inaf014.
5. Tian C, Gu X, Jiang C*, Ding Q*. Emerging roles of MRG15 in liver metabolic diseases. Trends Mol Med. 2024. 30(6):527-529.
6. Li S#, Jiang D#, Li X, Zhao Y, Gu X, Jiang C*, Ding Q*. CD157 selectively identifies hPSCs with enhanced hepatic differentiation capacity. Life Med. 2024. Inae 026.
7. Wu X, Jiang D, Wang Y, Li X, Liu X, Chen Y, Sun W, He R, Yang Y, Gu X, Jiang C*, Ding Q*. Modeling metabolic-associated steatohepatits with human pluripotent stem cell-derived liver organoids. Hepatol Commun. 2024. 8(12):e0585.
8. Chen Y#*, Chen L#, Wu X#, Zhao Y, Wang Y, Jiang D, Liu X, Zhou T, Li S, Wei Y, Liu Y, Hu C, Zhou B, Qin J, Ying H, Ding Q*. Acute liver steatosis translationally controls the epigenetic regulator MIER1 to promote liver regeneration in a study with male mice. Nat Commun. 2023. 14(1):1521.
9. Zhao Y#*, Li S#, Chen Y, Wang Y, Wei Y, Zhou T, Zhang Y, Yang Y, Chen L, Liu Y, Hu C, Zhou B, Ding Q*. Histone phosphorylation integrates the hepatic glucagon-PKA-CREB gluconeogenesis program in response to fasting. Mol Cell 2023. S1097-2765(23)00102-8. doi: 10.1016/j.molcel.2023.02.007.
10. Wu X, Jiang D, Li S*, Ding Q*. Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids. Cell Regen. 2023. 12(1):6. doi: 10.1186/s13619-022-00148-1.
11. Zhou T, Musunuru K, Lui K*, Ding Q*. Decoding liver fibrogenesis with single-cell technologies. Life Med. 2022. Inac040.
12. Tian C, Min X, Zhao Y, Wang Y, Wu X, Liu S, Dou W, Zhou T, Liu Y, Luo R, Li Z, Lui KO, Li Y, Zhou B, Ding Q*. MRG15 aggravates non-alcoholic steaohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM. J Hepatol. 2022. S0168-8278(22)02981-6.
13. Han J#*, Wang Y#*, Qiu Y, Sun D, Liu Y, Li Z, Zhou B, Zhang H, Xiao Y, Wu G*, Ding Q*. Single-cell sequencing unveils key contributions of immune cell populations in cancer-associated adipose wasting. Cell Discov. 2022. 8(1):122.?
14. Chen Y, Ding Q*. Optimized protocols for efficient gene editing in mouse hepatocytes in vivo using CRISPR-Cas9 technology. ?STAR Protoc. 2022. 3(1): 101062.
15. Qiu Y, Ding Q*. Optimized protocol for gene editing in adipocytes using CRISPR-Cas9 technology. STAR Protoc. 2021. 2: 100307.
16. Qiu Y, Liu X, Sun Y, Zeng X, Li S, Wei Y, Tian C, Ding Q*. In situ saturating mutagenesis screening identifies a functional genomic locus that regulates Ucp1 expression. Phenomics 2020.1:15-21.
17. Liu X, Yang Y, Qiu Y, Md. Reyad-ul-ferdous, Ding Q*, Wang Y*. SeqCor: correct the effect of gRNA sequences in CRISPR/Cas9 screenings by machine learning algorithm. J Genet Genomics. 2020. 47: 672-680.
18. Qiu Y, Yang Y, Wei Y, Liu X, Feng Z, Zeng X, Chen Y, Liu Y, Zhao Y, Chen L, Luo L, Ding Q*. Glyburide regulates UCP1 expression in adipocytes independent of K ATP channel blockade. iScience 2020; 23: 101446.
19. Ding Q*. Spotlight on gene therapy in China. Gene Ther. 2020; 27: 307-308.
20. Wei Y#, Tian C#, Zhao Y#, Liu X, Liu F, Li S, Chen Y, Qiu Y, Feng Z, Chen L, Zhou T, Ren X, Feng C, Liu Y, Yu W, Ying H, Ding Q*. MRG15 orchestrates rhythmic epigenomic remodeling and controls hepatic lipid metabolism. Nat Metab. 2020; 2:447-460.
21. Yang Y#, Liu X#, Li S, Chen Y, Zhao Y, Wei Y, Qiu Y, Liu Y, Zhou Z, Han J*, Wu G*, Ding Q*. Genome-scale CRISPR screening for potential targets of ginsenoside compound K. Cell Death Dis. 2020. 11: 39.
22. Zhao Y#, Feng Z#, Ding Q*. Type 2 Diabetes Variants in the SLC16A11 coding region are not loss-of-function mutations. Cell Rep. 2019. 29:1-4.
23. Feng Z, Wei Y, Zhang Y, Qiu Y, Liu X, Su L, Liang N, Yin H, Ding Q*. Identification of a rhodanine derivative BML-260 as a potent stimulator of UCP1 expression. Theranostics 2019. 9: 3501-3514.
24. Zhao Y#, Feng Z#, Zhang Y#, Sun Y, Chen Y, Liu X, Li S, Zhou T, Chen L, Wei Y, Ma D, Lui K, Ying H, Chen Y, Ding Q*. Gain-of-function mutations of SLC16A11 contribute to the pathogenesis of type 2 diabetes. Cell Rep. 2019. 26:884-892.
25. Qiu Y#, Sun Y#, Xu D, Yang Y, Liu X, Wei Y, Chen Y, Feng Z, Li S, Ferdous M, Zhao Y, Xu H, Lao Y*, Ding Q*. Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue. EBioMedicine 2018. 37:344-355.
26. Li S, Li M, Liu X, Yang Y, Wei Y, Chen Y, Qiu Y, Zhou T, Feng Z, Ma D, Fang J, Ying H, Wang H, Musunuru K, Shao S*, Zhao Y*, Ding Q*. Genetic and chemical screenings identify HDAC3 as a key regulator in hepatic differentiation of human pluripotent stem cells. Stem Cell Rep. 2018. 11:22-31.
27. Sun Y, Ding Q*. Genome engineering of stem cell organoids for disease modeling. Protein Cell 2017. 8:315-327.
28. Wei Y, Qiu Y, Chen Y, Liu G, Zhang Y, Xu L, Ding Q*. CRISPR/Cas9 with single guide RNA expression driven by small tRNA promoters showed reduced editing efficiency compared to U6 promoter. RNA 2017. 23:1-5.
29. Wei Y, Chen Y, Qiu Y, Zhao H, Liu G, Zhang Y, Meng Q, Wu G, Chen Y, Cai X, Wang H, Ying H, Zhou B, Liu M, Li D, Ding Q*. Prevention of muscle wasting by CRISPR/Cas9-mediated disruption of myostatin in vivo. Mol Ther. 2016. 24: 1889-91.
30. Chen Y, Liu X, Zhang Y, Wang H, Ying H, Liu M, Li D, Lui K, Ding Q*. A Self- restricted CRISPR System to Reduce Off- target Effects. Mol Ther. 2016. 24: 1508-10.
31. Wang X, Raghavan A, Chen T, Qiao L, Zhang Y, Ding Q*, Musunuru K*. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo. Arterioscler Thromb Vasc Biol. 2016. 143: 1475-81.
?
官方微信
